New advance for disease modification therapy in Parkinson's disease

Abstract

Therapy to halt or slow down the progression of neurodegeneration in Parkinson's disease (PD) is urgently demand. Disease modification therapy can modify the natural history of the disease and show neuroprotective effect in PD. Currently, many potential neuroprotective therapies are emerging. The review aims to summarize the new advances for disease modification therapies in PD including targeting drugs α-synuclein, LRRK2 gene, GBA gene, mitochondrial function, glucagon-like peptide-1 (GLP-1), neuroinflammation, calcium antagonist and iron chelating agent.

doi：10.3969/j.issn.1672⁃6731.2022.03.005